Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:0ccb59190801baf873e29b022989ac0b]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:0ccb59190801baf873e29b022989ac0b]

Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:0ccb59190801baf873e29b022989ac0b
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV [clinicaltrials:NCT01601626]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C) 48 weeks [clinicaltrials_resource:0ccb59190801baf873e29b022989ac0b]

Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:0ccb59190801baf873e29b022989ac0b
Bio2RDF identifier
0ccb59190801baf873e29b022989ac0b
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0ccb59190801baf873e29b022989ac0b
measure [clinicaltrials_vocabulary:measure]
Percent of participants whose ...... B vs Arm A and Arm B vs Arm C)
time frame [clinicaltrials_vocabulary:time-frame]
description
Two LPV 200 mg/RTV 50 mg fixed ...... e daily from entry to Week 72.
identifier
clinicaltrials_resource:0ccb59190801baf873e29b022989ac0b
title
Percent of participants whose ...... A and Arm B vs Arm C) 48 weeks
@en
inDataset
type
label
Percent of participants whose ...... b59190801baf873e29b022989ac0b]
@en